GO:0009154 purine ribonucleotide catabolic process: Nucleotide Turnover, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009154 describes the chemical reactions and pathways that break down purine ribonucleotides, the ribose-phosphate esters of adenine and guanine bases.
• Purine ribonucleotide catabolism is essential for balancing nucleotide pools, recycling purine bases, and producing uric acid in humans.
• Key enzymes include purine nucleoside phosphorylase (PNP), xanthine dehydrogenase (XDH), and adenosine deaminase (ADA), which catalyze sequential dephosphorylation, deamination, and phosphorolysis steps.
• Dysregulated purine catabolism is linked to hyperuricemia, gout, immunodeficiency, and cancer metabolism.
• CRISPR knockout, point mutation, and knock-in models enable causal testing of catabolic enzyme function in cell and animal systems.
• Targeting purine catabolic enzymes is an active area for drug discovery, including inhibitors of N5-CAIR mutase and purinome-directed compounds.
Description
Purine ribonucleotide catabolic process (GO:0009154) is the biological process that breaks down purine ribonucleotides, which are compounds consisting of a purine base linked to a ribose sugar and esterified with a phosphate group. This process is fundamental to nucleotide homeostasis, allowing cells to salvage purine bases or eliminate excess nitrogen as uric acid. Researchers study this pathway because its dysregulation contributes to metabolic disorders, immune dysfunction, and cancer. The pathway involves a coordinated series of enzymatic steps that convert nucleotides such as AMP and GMP into nucleosides, free bases, and ultimately uric acid. Understanding these reactions provides insight into how cells manage purine availability for DNA/RNA synthesis, energy metabolism, and signaling. The catabolic process is also a source of extracellular purines that modulate inflammatory responses. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of GO:0009154, its genes, regulation, disease relevance, and experimental models.
purine ribonucleotide catabolic process At A Glance
| GO ID | GO:0009154 |
|---|---|
| GO term | purine ribonucleotide catabolic process |
| Ontology | biological_process |
| Synonym | purine ribonucleotide breakdown; purine ribonucleotide catabolism; purine ribonucleotide degradation |
| Major function | Breakdown of purine ribonucleotides (AMP, GMP, IMP) into nucleosides, free bases, and uric acid |
| Key enzymes | PNP, XDH, ADA, AMPD, GDA, NT5C |
| Pathway context | Nucleotide metabolism; purine salvage and degradation |
| Disease relevance | Hyperuricemia, gout, immunodeficiency, cancer, inflammatory disorders |
What Is GO:0009154?
GO:0009154, purine ribonucleotide catabolic process, is defined as the chemical reactions and pathways resulting in the breakdown of a purine ribonucleotide, a compound consisting of a ribonucleoside (a purine base linked to a ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar. In simpler terms, it is the set of enzymatic steps that dismantle purine nucleotides into smaller molecules, ultimately contributing to purine recycling or excretion.
Why Is purine ribonucleotide catabolic process Important in Cell Biology?
Purine ribonucleotide catabolism is critical for maintaining cellular nucleotide balance and preventing the toxic accumulation of purine intermediates. It supplies salvageable purine bases and regulates the availability of adenosine and guanosine, which act as signaling molecules in inflammation and immunity. Defects in catabolic enzymes cause severe human disorders, including immunodeficiency and hyperuricemia. Moreover, cancer cells often reprogram purine metabolism to support rapid proliferation, making this pathway a target for therapeutic intervention.
• Maintains intracellular nucleotide pools by removing excess purine ribonucleotides.
• Produces uric acid as the final product of purine catabolism in humans.
• Regulates adenosine and guanosine levels that modulate immune and inflammatory responses.
• Provides purine bases for salvage pathways, conserving energy.
• Enzyme deficiencies (e.g., ADA, PNP) cause severe immunodeficiency.
• Overactivity contributes to hyperuricemia and gout.
• Altered in cancer metabolism, supporting proliferation and survival.
• Targeted by small-molecule inhibitors for drug discovery.
• Influences senescence-associated secretory phenotype via purine biosynthesis crosstalk.
• Serves as a model for studying metabolic pathway regulation and enzyme evolution.
What Happens During purine ribonucleotide catabolic process?
Dephosphorylation of purine ribonucleotides
In simple terms: The phosphate group is removed from the nucleotide.
The first step in purine ribonucleotide catabolism often involves dephosphorylation of nucleotides such as AMP, GMP, and IMP by nucleotidases (e.g., NT5C, NT5E). This yields purine ribonucleosides (adenosine, guanosine, inosine), which can then be further degraded or salvaged. This step is regulated by the availability of substrates and the activity of specific phosphatases.
Deamination of purine nucleosides
In simple terms: An amino group is removed from the nucleoside.
Adenosine deaminase (ADA) converts adenosine to inosine, and guanosine deaminase (GDA) converts guanosine to xanthosine. These deamination reactions are crucial for purine catabolism and for regulating adenosine signaling. ADA deficiency leads to accumulation of toxic deoxyadenosine, causing severe combined immunodeficiency.
Phosphorolysis of purine nucleosides
In simple terms: The sugar is removed to release the free base.
Purine nucleoside phosphorylase (PNP) catalyzes the reversible phosphorolysis of inosine, guanosine, and deoxyinosine to their respective purine bases (hypoxanthine, guanine) and ribose-1-phosphate. This step is central to purine salvage and catabolism. PNP deficiency results in immunodeficiency due to accumulation of deoxyguanosine.
Oxidation of purine bases to uric acid
In simple terms: The free bases are converted into uric acid.
Hypoxanthine is oxidized to xanthine and then to uric acid by xanthine dehydrogenase (XDH). Guanine is deaminated to xanthine by guanine deaminase (GDA) and then oxidized to uric acid. Uric acid is the final product of purine catabolism in humans. XDH activity is a major source of reactive oxygen species and is linked to gout and hyperuricemia.
Salvage and excretion
In simple terms: Some bases are recycled, while uric acid is excreted.
Purine bases can be salvaged by HGPRT and APRT to regenerate nucleotides, conserving energy. The remaining uric acid is excreted by the kidneys and intestine. The balance between catabolism and salvage is critical for purine homeostasis.
Key Genes Involved in GO:0009154 purine ribonucleotide catabolic process
The following genes encode enzymes and transporters directly involved in purine ribonucleotide catabolic process (GO:0009154).
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADA | Adenosine deaminase; converts adenosine to inosine | Immunodeficiency; adenosine signaling |
| PNP | Purine nucleoside phosphorylase; phosphorolysis of nucleosides | Immunodeficiency; purine salvage |
| XDH | Xanthine dehydrogenase; oxidizes hypoxanthine to xanthine and uric acid | Gout; hyperuricemia; oxidative stress |
| GDA | Guanine deaminase; deaminates guanine to xanthine | Purine catabolism; neuroprotection |
| AMPD1 | AMP deaminase 1; converts AMP to IMP | Myogenic hyperuricemia; muscle metabolism |
| AMPD2 | AMP deaminase 2; converts AMP to IMP | Purine homeostasis; neurological disorders |
| AMPD3 | AMP deaminase 3; converts AMP to IMP | Cardiac and skeletal muscle metabolism |
| NT5C1A | Cytosolic 5'-nucleotidase; dephosphorylates AMP | Purine catabolism; muscle energy |
| NT5C2 | Cytosolic 5'-nucleotidase; dephosphorylates IMP/GMP | Purine analog metabolism; leukemia |
| NT5E | Ecto-5'-nucleotidase (CD73); dephosphorylates AMP to adenosine | Immune regulation; cancer |
| ENTPD1 | Ectonucleoside triphosphate diphosphohydrolase 1 (CD39); hydrolyzes ATP/ADP | Inflammation; thrombosis |
| APRT | Adenine phosphoribosyltransferase; salvages adenine | Adenine salvage; kidney stones |
| HPRT1 | Hypoxanthine phosphoribosyltransferase 1; salvages hypoxanthine | Lesch-Nyhan syndrome; gout |
| IMPDH1 | Inosine monophosphate dehydrogenase 1; converts IMP to XMP | GTP synthesis; cancer |
| IMPDH2 | Inosine monophosphate dehydrogenase 2; converts IMP to XMP | GTP synthesis; immune function |
| PAICS | Phosphoribosylaminoimidazole carboxylase; de novo purine biosynthesis | Senescence; cancer metabolism |
| ACSS2 | Acetyl-CoA synthetase 2; links acetyl-CoA to purine biosynthesis | Senescence-associated secretory phenotype |
How Is purine ribonucleotide catabolic process Regulated?
Purine ribonucleotide catabolism is regulated at multiple levels. Enzyme expression is controlled by transcription factors responsive to nucleotide availability, such as the mTOR pathway, which senses purine levels and modulates biosynthetic and catabolic fluxes. Post-translational modifications, including acetylation of PAICS by ACSS2, can limit purine biosynthesis and indirectly affect catabolic balance. Allosteric regulation of key enzymes (e.g., AMPD by ATP and GTP) fine-tunes flux through the pathway. In inflammatory contexts, extracellular purine release and signaling via adenosine receptors regulate catabolic enzyme expression. Additionally, feedback inhibition by purine nucleotides controls the first committed steps of de novo biosynthesis, indirectly influencing catabolic rates.
purine ribonucleotide catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADA | Severe combined immunodeficiency (SCID) | ADA knockout cell line; knock-in of patient mutations |
| PNP | Immunodeficiency; purine nucleoside accumulation | PNP knockout mice; CRISPR KO in T cells |
| XDH | Gout; hyperuricemia; oxidative stress | XDH knockout cells; point mutation of catalytic residues |
| HPRT1 | Lesch-Nyhan syndrome; gout | HPRT1 knockout cells; knock-in of disease alleles |
| NT5E | Ecto-5'-nucleotidase deficiency; immune dysregulation | NT5E knockout; overexpression of CD73 |
Immunodeficiency and purine catabolic enzyme defects
Deficiencies in ADA and PNP cause severe combined immunodeficiency (SCID) due to accumulation of toxic deoxynucleotides in lymphocytes. These disorders highlight the critical role of purine catabolism in immune cell survival and function. Research using knockout models has elucidated the metabolic basis of these diseases.
Hyperuricemia and gout
Overactivity of xanthine dehydrogenase (XDH) and increased purine catabolism lead to elevated uric acid, causing gout and hyperuricemia. Myogenic hyperuricemia results from increased AMP deamination in muscle during exercise. Inhibitors of XDH, such as allopurinol, are used clinically, and research continues to target other catabolic enzymes.
Cancer metabolism and senescence
Cancer cells often upregulate purine biosynthesis and salvage to support proliferation, while catabolic enzymes can be dysregulated. ACSS2-mediated acetylation of PAICS limits purine biosynthesis and promotes senescence-associated secretory phenotype, linking catabolism to tumor suppression. Targeting purine metabolic enzymes is a promising anticancer strategy.
Neurological and inflammatory disorders
Adenosine, a product of purine catabolism, modulates inflammation and neurotransmission. Dysregulated purine catabolism contributes to neuroinflammation and neurodegeneration. Enzymes like CD73 (NT5E) and CD39 (ENTPD1) are therapeutic targets in inflammatory diseases.
From purine ribonucleotide catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ADA affect lymphocyte survival? | ADA knockout cell line (CRISPR KO) |
| Does a point mutation in XDH alter uric acid production? | XDH point-mutation knock-in (e.g., catalytic residue) |
| Can overexpression of NT5E increase adenosine levels? | NT5E overexpression stable cell line |
| Does tagging PNP with GFP affect its localization? | Tagged knock-in of PNP-GFP |
| Does ACSS2-mediated PAICS acetylation regulate purine catabolism? | PAICS acetylation-site mutant knock-in |
| Can CRISPR library screening identify modifiers of purine catabolism? | Genome-wide CRISPR knockout library in reporter cells |
How to Study the purine ribonucleotide catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Levels of purine nucleotides, nucleosides, uric acid | Quantifying pathway flux in KO cells |
| Stable isotope tracing | Incorporation of labeled precursors into purine metabolites | Determining de novo vs salvage flux |
| Enzyme activity assay | Catalytic activity of ADA, PNP, XDH | Validating point mutations |
| CRISPR knockout library screen | Gene essentiality or reporter activation | Identifying novel regulators |
| RNA-seq | Transcript levels of catabolic genes | Assessing transcriptional regulation |
| Proteomics | Protein abundance and modifications | Detecting acetylation or phosphorylation |
| Immunofluorescence | Subcellular localization of enzymes | Studying compartmentalization |
| Adenosine sensor imaging | Extracellular adenosine levels | Real-time monitoring of catabolism |
Metabolomics and flux analysis
Mass spectrometry-based metabolomics quantifies purine nucleotides, nucleosides, and uric acid to assess catabolic flux. Stable isotope tracing with 13C/15N-labeled precursors reveals pathway activity and regulation.
Enzyme activity assays
In vitro assays measure the activity of ADA, PNP, XDH, and other enzymes using spectrophotometric or HPLC-based detection of substrates and products. These assays are used to validate CRISPR knockout or point-mutation effects.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens can identify genes that regulate purine catabolism. Reporter cell lines expressing fluorescent sensors for adenosine or uric acid enable high-throughput screening.
Transcriptomics and proteomics
RNA-seq and proteomics measure expression changes in purine catabolic enzymes under different conditions. Post-translational modifications such as acetylation are detected by mass spectrometry.
How CRISPR Can Be Used to Study GO:0009154 purine ribonucleotide catabolic process
Knockout
CRISPR knockout of genes such as ADA, PNP, or XDH in cell lines or primary cells abolishes enzyme activity, allowing researchers to study metabolic consequences, compensatory pathways, and disease phenotypes. Knockout models are essential for validating drug targets and understanding immunodeficiency mechanisms.
Point Mutation
Point mutations introduced by CRISPR base editing or HDR can mimic human disease alleles, such as catalytic-dead XDH or ADA mutations. These models help dissect the specific contribution of enzyme activity versus protein interactions.
Knock-in
Knock-in of tagged versions (e.g., GFP, FLAG) of catabolic enzymes enables live-cell imaging, immunoprecipitation, and proteomic studies. Knock-in of patient mutations into endogenous loci provides physiologically relevant disease models.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of genes like NT5E or ACSS2 increases enzyme levels, allowing gain-of-function studies. Overexpression models are used to test whether increased catabolism drives phenotypes such as immune suppression or senescence.
How EDITGENE Supports purine ribonucleotide catabolic process Research
Researchers studying purine ribonucleotide catabolic process-related genes often need to determine whether a candidate gene is causally involved in metabolic regulation, disease progression, or drug response. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes in this pathway.
Contact EDITGENE today to design your custom CRISPR model for purine ribonucleotide catabolic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| HINT1 Knockout HEK293 Cell Line | EDJ-KQ4869 | Human | 3094 | Details Get a Quote |
| NT5C2 Knockout HEK293 Cell Line | EDJ-KQ7761 | Human | 22978 | Details Get a Quote |
| NT5DC4 Knockout HEK293 Cell Line | EDJ-KQ14506 | Human | 284958 | Details Get a Quote |
| NT5C2 Knockout A-549 Cell Line | EDJ-KQ33213 | Human | 22978 | Details Get a Quote |
| NT5C2 Knockout HCT 116 Cell Line | EDJ-KQ33214 | Human | 22978 | Details Get a Quote |
| NT5C2 Knockout HeLa Cell Line | EDJ-KQ33215 | Human | 22978 | Details Get a Quote |
| HINT1 Knockout A-549 Cell Line | EDJ-KQ27655 | Human | 3094 | Details Get a Quote |
| HINT1 Knockout HCT 116 Cell Line | EDJ-KQ27656 | Human | 3094 | Details Get a Quote |
| HINT1 Knockout HeLa Cell Line | EDJ-KQ27657 | Human | 3094 | Details Get a Quote |
Displaying Records 1 To 9 Of 9 Records
Frequently Asked Questions About purine ribonucleotide catabolic process
What is GO:0009154?
GO:0009154 is the Gene Ontology term for purine ribonucleotide catabolic process, the breakdown of purine ribonucleotides into nucleosides, free bases, and uric acid.
What genes are involved in purine ribonucleotide catabolic process?
Key genes include ADA, PNP, XDH, GDA, AMPD1/2/3, NT5C1A, NT5C2, NT5E, and ENTPD1.
What is the end product of purine ribonucleotide catabolism in humans?
Uric acid is the final product of purine catabolism in humans.
How is purine ribonucleotide catabolism regulated?
It is regulated by enzyme expression, allosteric feedback, post-translational modifications, and signaling pathways such as mTOR.
What diseases are associated with defects in purine catabolism?
ADA and PNP deficiencies cause immunodeficiency; XDH overactivity causes gout and hyperuricemia.
Which enzymes catalyze the deamination step?
Adenosine deaminase (ADA) and guanine deaminase (GDA) catalyze deamination of adenosine and guanosine, respectively.
What is the role of xanthine dehydrogenase in purine catabolism?
XDH oxidizes hypoxanthine to xanthine and then to uric acid, contributing to uric acid production and oxidative stress.
How can CRISPR be used to study purine ribonucleotide catabolic process?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of enzyme function in this pathway.
What methods measure purine catabolic flux?
LC-MS metabolomics, stable isotope tracing, and enzyme activity assays are commonly used.
Is purine ribonucleotide catabolism a drug target?
Yes, inhibitors of XDH (e.g., allopurinol) and other enzymes are used or in development for gout, cancer, and immune disorders.
Conclusion
Purine ribonucleotide catabolic process (GO:0009154) is a central metabolic pathway that maintains nucleotide homeostasis, regulates immune signaling, and contributes to human disease when dysregulated. Understanding its enzymatic steps and regulation provides opportunities for therapeutic intervention in immunodeficiency, gout, and cancer. CRISPR-based models are powerful tools for dissecting gene function in this pathway, and EDITGENE offers comprehensive services to accelerate such research.
References
- 1. Pareek V et al.. 2021. Human de novo purine biosynthesis.. Crit Rev Biochem Mol Biol 56(1):1-16 PMID: 33179964
- 2. Linden J et al.. 2019. Purine Release, Metabolism, and Signaling in the Inflammatory Response.. Annu Rev Immunol 37:325-347 PMID: 30676821
- 3. Yang L et al.. 2025. ACSS2 drives senescence-associated secretory phenotype by limiting purine biosynthesis through PAICS acetylation.. Nat Commun 16(1):2071 PMID: 40021646
- 5. Sharma MF et al.. 2024. Carboxylation in de novo purine biosynthesis.. Methods Enzymol 708:389-424 PMID: 39572148
- 6. Yamasaki T et al.. 1996. [Myogenic hyperuricemia].. Nihon Rinsho 54(12):3343-8 PMID: 8976117
- 7. Belfon KKJ et al.. 2023. Structure-Guided Discovery of N(5)-CAIR Mutase Inhibitors.. Biochemistry 62(17):2587-2596 PMID: 37552766
- 8. Murray JM et al.. 2009. Targeting the purinome.. Methods Mol Biol 575:47-92 PMID: 19727611
